Drug reference
vonoprazan
Potassium-competitive acid blocker · Antacid
Potassium-competitive acid blockerAntacid
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Potassium-competitive acid blockers are weak bases that bind competitively and reversibly to the potassium binding site of the H+/K+-ATPase following protonation. This prevents access of K+ cations to their binding site, blocking activation of the H+/K+-ATPase.
Indications
Gastroduodenal ulcersHealing and prevention of erosive esophagitisGastric protection in patients taking aspirin or NSAIDsHelicobacter pylori eradicationGastroesophageal reflux disease
Dosing
- Adult
- 10–20 mg daily
Pharmacokinetics
Onset
Early onset of action with immediate full effect from the first dose.
Half-life
2 to 9 h
Metabolism
Mainly metabolized in the liver via CYP3A4/5.
Side effects
Common
DiarrheaNasopharyngitisDyspepsiaHeadacheAbdominal pain
Related guidelines
Helicobacter pylori infection
ICMR · Gastroenterology · 2021
Gastro-oesophageal reflux disease
ISG · Gastroenterology · 2022
Gastric premalignant conditions
ACG · Gastroenterology · 2025
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Cardiovascular disease prevention
ESC · Cardiology · 2021
Other Potassium-competitive acid blocker drugs
Ask House about vonoprazan
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team